Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer.

Abstract

INTRODUCTION:

Intraperitoneal (i.p.) chemotherapy has been extensively studied in the ovarian cancer field. Despite the fact that three large randomized trials that were conducted in the United States showed survival benefit, meta-analysis also showed survival benefit and the National Cancer Institute (NCI) released a clinical announcement recommending i.p. chemotherapy for optimally debulked advanced stage ovarian cancer in 2006, i.p. chemotherapy has not been widely accepted by the gynecologic oncology community, mainly because of its toxicities.

AREAS COVERED:

In this review, previously available evidence, new evidence published since the NCI clinical announcement and ongoing clinical trials will be discussed.

EXPERT OPINION:

Three currently ongoing randomized Phase III trials will provide extremely important information about whether a less toxic i.p. regimen using carboplatin will be beneficial for patients with advanced ovarian cancer. They are important because it may be possible to solve many of the questions or unmet needs in i.p. chemotherapy by combining these three trials.

• Authors: Keiichi Fujiwara, Shoji Nagao, Eriko Aotani, Kosei Hasegawa
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 14 Issue 13 Pg. 1797-806 (Sep 2013) ISSN: 1744-7666 [Electronic] England
• PMID: 23915009 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Bevacizumab
• Carboplatin
• Paclitaxel
• Cisplatin

Topics

• Animals
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Agents (administration & dosage)
• Bevacizumab
• Carboplatin (administration & dosage)
• Cisplatin (administration & dosage)
• Female
• Humans
• Infusions, Parenteral
• Ovarian Neoplasms (drug therapy)
• Paclitaxel (administration & dosage)